Advanced search
1 file | 1.46 MB

PEGylated and functionalized aliphatic polycarbonate polyplex nanoparticles for intravenous administration of HDAC5 siRNA in cancer therapy

Author
Organization
Abstract
Guanidine and morpholine functionalized aliphatic polycarbonate polymers are able to deliver efficiently histone deacetylase 5 (HDAC5) siRNA into the cytoplasm of cancer cells in vitro leading to a decrease of cell proliferation were previously developed. To allow these biodegradable and biocompatible polyplex nanoparticles to overcome the extracellular barriers and be effective in vivo after an intravenous injection, polyethylene glycol chains (PEG(750) or PEG(2000)) were grafted on the polymer structure. These nanoparticles showed an average size of about 150 nm and a slightly positive zeta-potential with complete siRNA complexation. Behavior of PEGylated and non-PEGylated polyplexes were investigated in the presence of serum, in terms of siRNA complexation (fluorescence correlation spectroscopy), size (dynamic light scattering and single-particle tracking), interaction with proteins (isothermal titration calorimetry) and cellular uptake. Surprisingly, both PEGylated and non-PEGylated formulations presented relatively good behavior in the presence of fetal bovine serum (FBS). Hemocompatibility tests showed no effect of these polyplexes on hemolysis and coagulation. In vivo biodistribution in mice was performed and showed a better siRNA accumulation at the tumor site for PEGylated polyplexes. However, cellular uptake in protein-rich conditions showed that PEGylated polyplex lost their ability to interact with biological membranes and enter into cells, showing the importance to perform in vitro investigations in physiological conditions closed to in vivo situation. In vitro, the efficiency of PEGylated nanoparticles decreases compared to non-PEGylated particles, leading to the loss of the antiproliferative effect on cancer cells.
Keywords
siRNA, polyplex nanoparticles, intravenous administration, aliphatic polycarbonate, polyethylene glycol, protein corona, HISTONE DEACETYLASE INHIBITORS, RING-OPENING POLYMERIZATION, SYSTEMIC GENE DELIVERY, DRUG-DELIVERY, CELLULAR UPTAKE, PROTEIN CORONA, BIOLOGICAL-FLUIDS, CELLS, DESIGN, BARRIERS

Downloads

  • PEGylated.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 1.46 MB

Citation

Please use this url to cite or link to this publication:

Chicago
Frère, Antoine, Alexandra Baroni, Elodie Hendrick, Anne-Sophie Delvigne, François Orange, Olivier Peulen, George Dakwar, et al. 2017. “PEGylated and Functionalized Aliphatic Polycarbonate Polyplex Nanoparticles for Intravenous Administration of HDAC5 siRNA in Cancer Therapy.” Acs Applied Materials & Interfaces 9 (3): 2181–2195.
APA
Frère, A., Baroni, A., Hendrick, E., Delvigne, A.-S., Orange, F., Peulen, O., Dakwar, G., et al. (2017). PEGylated and functionalized aliphatic polycarbonate polyplex nanoparticles for intravenous administration of HDAC5 siRNA in cancer therapy. ACS APPLIED MATERIALS & INTERFACES, 9(3), 2181–2195.
Vancouver
1.
Frère A, Baroni A, Hendrick E, Delvigne A-S, Orange F, Peulen O, et al. PEGylated and functionalized aliphatic polycarbonate polyplex nanoparticles for intravenous administration of HDAC5 siRNA in cancer therapy. ACS APPLIED MATERIALS & INTERFACES. 2017;9(3):2181–95.
MLA
Frère, Antoine, Alexandra Baroni, Elodie Hendrick, et al. “PEGylated and Functionalized Aliphatic Polycarbonate Polyplex Nanoparticles for Intravenous Administration of HDAC5 siRNA in Cancer Therapy.” ACS APPLIED MATERIALS & INTERFACES 9.3 (2017): 2181–2195. Print.
@article{8520080,
  abstract     = {Guanidine and morpholine functionalized aliphatic polycarbonate polymers are able to deliver efficiently histone deacetylase 5 (HDAC5) siRNA into the cytoplasm of cancer cells in vitro leading to a decrease of cell proliferation were previously developed. To allow these biodegradable and biocompatible polyplex nanoparticles to overcome the extracellular barriers and be effective in vivo after an intravenous injection, polyethylene glycol chains (PEG(750) or PEG(2000)) were grafted on the polymer structure. These nanoparticles showed an average size of about 150 nm and a slightly positive zeta-potential with complete siRNA complexation. Behavior of PEGylated and non-PEGylated polyplexes were investigated in the presence of serum, in terms of siRNA complexation (fluorescence correlation spectroscopy), size (dynamic light scattering and single-particle tracking), interaction with proteins (isothermal titration calorimetry) and cellular uptake. Surprisingly, both PEGylated and non-PEGylated formulations presented relatively good behavior in the presence of fetal bovine serum (FBS). Hemocompatibility tests showed no effect of these polyplexes on hemolysis and coagulation. In vivo biodistribution in mice was performed and showed a better siRNA accumulation at the tumor site for PEGylated polyplexes. However, cellular uptake in protein-rich conditions showed that PEGylated polyplex lost their ability to interact with biological membranes and enter into cells, showing the importance to perform in vitro investigations in physiological conditions closed to in vivo situation. In vitro, the efficiency of PEGylated nanoparticles decreases compared to non-PEGylated particles, leading to the loss of the antiproliferative effect on cancer cells.},
  author       = {Fr{\`e}re, Antoine and Baroni, Alexandra and Hendrick, Elodie and Delvigne, Anne-Sophie and Orange, Fran\c{c}ois and Peulen, Olivier and Dakwar, George and Diricq, J{\'e}r{\^o}me and Dubois, Philippe and Evrard, Brigitte and Remaut, Katrien and Braeckmans, Kevin and De Smedt, Stefaan and Laloy, Julie and Dogn{\'e}, Jean-Michel and Feller, Georges and Mespouille, Laetitia and Mottet, Denis and Piel, G{\'e}raldine},
  issn         = {1944-8244},
  journal      = {ACS APPLIED MATERIALS \& INTERFACES},
  language     = {eng},
  number       = {3},
  pages        = {2181--2195},
  title        = {PEGylated and functionalized aliphatic polycarbonate polyplex nanoparticles for intravenous administration of HDAC5 siRNA in cancer therapy},
  url          = {http://dx.doi.org/10.1021/acsami.6b15064},
  volume       = {9},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: